Swansea University pioneer ‘DIY’ analysis of blood samples device

Please note, this page has been archived and is no longer being updated.

Professor Huw Summers, Chair of Nanotechnology for Health and Head of the Multidisciplinary Nanotechnology Centre (MNC) at Swansea University, is leading research into a device which could allow non-technical users to analyse blood samples themselves, potentially revolutionising the turnaround time between sample acquisition and assessment delivery.

The project, run jointly with a physics group at Cardiff University led by Professor Peter Smowton is being funded by the Engineering and Physical Sciences Research Council (EPSRC) and will produce a device known as an “Integrated III-V Haemocytometer”, a capillary driven, microscale disposable chip instrument for the analysis of blood samples for non-technical users. 

Professor Summers, who is also a Senior Affiliate Member of the Methodist Hospital Research Institute in Houston, Texas, said: “The assessment of human health from analysis of blood samples is one of the most widespread medical diagnostic procedures; with thousands of patients providing samples every day in hundreds of clinics and surgeries across the UK.

“However, it remains a slow process because samples have to be sent to a limited number of specialist central services in health trusts, with a turnaround of days between sample acquisition and assessment delivery. It is expensive, both in terms of direct cost of the analysis and costs due to deterioration of patient health as a result of the time delay in accessing results.”

 “The Integrated III-V Haemocytometer is a microscale disposable chip instrument for non-technical users that provides established and understood diagnostic parameters.

“The basic device will consist of lasers and detectors integrated around a fluid channel to facilitate counting, scattering and wavelength dependent absorption measurements. This will differentiate red blood cells from white blood cells, discriminate between the main white blood cell types - monocyte, lymphocyte, neutrophil and granulocyte - and provide cell counts of these sub groups.

“We have blood analysis experts working on the project, and co-workers focused on cell cycle and anti-cancer research will interact and maximise the benefits of the device that goes well beyond current blood test capability.”

 “The microscale system is advantageous in a variety of ways, for example, microscaling reduces the volume of blood required, changing the way blood-based diagnostics are used. In this instance, immediate and quasi-continuous monitoring of the haematological state becomes feasible and can be used in acute situations such as surgery or childbirth. This also offers, with further development, a realistic route to continuous monitoring during everyday life.

There are also significant commercial benefits, with a UK manufacturing supply chain already identified. Professor Summers said: “Semiconductor micro fabrication will allow for mass manufacture of low cost systems, shifting the cost of blood testing from technician to test kit and introducing a distributed cost model (pay per kit) rather than a single, major capital investment.”